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Abstract
Purpose—Lymphocytic infiltration of tumors predicts improved survival in breast cancer
patients. Previous studies have suggested that this survival benefit is confined predominantly to
the basal-like subtype. Immune infiltration in ovarian tumors is also associated with improved
prognosis. Currently, it is unclear what aspects of the immune response mediate this improved
outcome.
Experimental Design—Using The Cancer Genome Atlas (TCGA) mRNA-seq data and a large
microarray data set, we evaluated adaptive immune gene expression by genomic subtype in breast
and ovarian cancer. To investigate B-cells observed to be prognostic within specific subtypes, we
developed methods to analyze B-cell population diversity and degree of somatic hypermutation
(SHM) from B-cell receptor (BCR) sequences in mRNA-seq data.
Results—Improved metastasis-free/progression-free survival was correlated with B-cell gene
expression signatures, which were restricted mainly to the basal-like and HER2-enriched breast
cancer subtypes and the immunoreactive ovarian cancer subtype. Consistent with a restricted
epitope-driven response, a subset of basal-like and HER2-enriched breast tumors and
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immunoreactive ovarian tumors showed high expression of a low-diversity population of BCR
gene segments. More BCR segments showed improved prognosis with increased expression in
basal-like breast tumors and immunoreactive ovarian tumors compared with other subtypes.
Basal-like and HER2-enriched tumors exhibited more BCR sequence variants in regions
consistent with somatic hypermutation.
Conclusion—Taken together, these data suggest the presence of a productive and potentially
restricted anti-tumor B-cell response in basal-like breast and immunoreactive ovarian cancers.
Immunomodulatory therapies that support B-cell responses may be a promising therapeutic
approach to targeting these B-cell infiltrated tumors.
Introduction
The role of tumor-infiltrating lymphocytes (TILs) in breast cancer is not fully understood,
although multiple studies have shown an association between the presence of TILs and an
improved prognosis (1–5). TILs in breast tumors are predominantly cytotoxic (CD8+) T-
cells (6, 7), and the proportion of CD8+ T-cells may be prognostic (4, 5, 8). In contrast, TILs
of the regulatory T-cell phenotype (CD4+CD25+FoxP3+ Tregs) are associated with poorer
outcomes in breast cancer (9, 10). The role of B-cell TILs in human breast cancer is not as
clear as that of T-cell TILs. Using gene expression profiling, our group and others have
showed that gene signatures representing B-cells, plasmablasts, plasma cells and
immunoglobulin predicted favorable clinical outcome in ER+ and ER− breast tumors(11–
15). In this manuscript, these are referred to as B-cell signatures; while plasmablasts and
plasma cells are known to infiltrate some breast tumors, we use the term “B-cell TIL” here
to refer to any TIL in the B-cell lineage. The presence of B-cell TILs as assessed by
immunohistochemistry (IHC) has also been shown to be an independent prognostic feature
in breast cancer (16). Studies of small numbers of breast tumors have shown the B-cell
response in these tumors to be clonally expanded, with evidence of having undergone class
switching and somatic hypermutation (17–22). This strongly suggested that in some breast
tumors there may be a clonally restricted, antigen-directed B-cell anti-tumor response.
Several studies have identified auto-antibodies in breast cancer patients, including antibodies
against improperly processed β-actin in some medullary breast cancers, although the
association between such auto-antibodies and patient survival is unclear (18, 21, 23).
Together, these findings provide evidence that B-cell TILs may be important in affecting
breast cancer biology and progression.
Human breast cancer is a heterogeneous disease, with individual tumors varying according
to morphology, natural history, and response to therapy. Gene expression analyses have
identified at least five distinct genomic subtypes of breast cancer: luminal A, luminal B,
HER2-enriched, basal-like, and claudin-low, as well as a normal-like group (24–28). The
prognostic value of both T and B-cell TILs may be restricted to a subset of highly immune-
infiltrated breast tumors (14). Basal-like breast tumors, in particular, appear to have
beneficial TILs (5, 15). Multiple groups have identified signatures of lymphocyte-related
gene expression that are overrepresented in basal-like breast tumors and predict better
survival(14, 15); in contrast, luminal A breast tumors show low levels of lymphocytic
infiltrate(5).
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Comprehensive genomic profiling of multiple tumor types in TCGA has shown there is a
strong similarity between basal-like breast cancer and serous ovarian cancer (24). These two
tumor types exhibit a similar mutational spectrum and share many of the same driver events
(i.e. TP53 loss, RB1 loss, c-MYC gain, etc.). Like basal-like breast cancer, many ovarian
tumors are rich in TILs. Analysis of TCGA serous ovarian cancer gene expression identified
four genomic subtypes: mesenchymal, proliferative, differentiated, and immunoreactive(29).
The immunoreactive subtype, in particular, showed high expression of T-cell chemokine
ligands and lymphocyte-related genes. Furthermore, a number of studies have shown the
presence of T and B-cell TILs is a positive prognostic feature in ovarian cancer (30–33). As
in breast cancer, the precise role of B-cell TILs is less understood than that of T-cell TILs.
These data suggest that, like basal-like breast cancer, serous ovarian cancer may be a likely
candidate for identifying a productive anti-tumor T-cell and/or B-cell TIL response.
If there is an effective, subtype-specific antitumor response mediated by B-cell TILs, this
presents the possibility of subtype-specific immunogenic epitopes that could promote
development of a subtype-specific antibody response. While some studies have identified
antigen-directed TIL clones in breast tumors (18–22), currently the degree to which TILs are
antigen-directed is unknown. The development of a mature B-cell response following
antigen stimulation depends on a number of processes that occur during the germinal center
reaction, including clonal expansion and antibody class switching (34, 35). While in the
germinal center, B-cells undergo somatic hypermutation (SHM), whereby mutations at BCR
loci are introduced to enhance B-cell receptor (BCR) affinity. Mutations occur preferentially
in “hot spot” nucleotide positions, particularly within the antigen-binding complementarity-
determining regions (CDRs), and they favor replacements and transitions(36). In a tumor-
antigen driven response, the TIL population is expected to be enriched for one or more
“dominant clones” exhibiting BCR characteristics consistent with somatic hypermutation.
Here, using a novel approach to characterize B-cell responses from short read mRNA-seq
data, we demonstrate subtype-specific enrichment of B-cell gene segments in basal-like and
HER2-enriched breast cancer and in immunoreactive ovarian cancer. We show evidence of
clonal restriction of the B-cell response in these three tumor types, and mutation patterns
consistent with SHM in basal-like and HER2-enriched breast cancer. These findings suggest
an important role for the endogenous B-cell response specifically in these tumor subtypes.
Methods
Data Sets
The breast cancer data set used for all analyses except the survival analysis of gene
expression signatures was the TCGA data set of 819 mRNA-seq samples, comprising 728
breast tumors and 91 normal breast samples (see TCGA Data Portal at https://tcga-
data.nci.nih.gov/tcga/, CGHub at https://cghub.ucsc.edu/). This 728 sample set is an
extension of the 480 tumors previously profiled by microarray(24), but these 480 plus 350
new samples have all been assayed by mRNA-seq using Illumina 2×50bp sequencing as
described by the TCGA in an evaluation of Lung Squamous samples(37). Gene expression
values were represented as RSEM (RNA-seq by Expectancy-Maximization) data normalized
within-sample to the upper quartile of total reads as previously described (37). These data
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subtype was assigned within the set of 728 mRNA-seq samples using the PAM50 assay
(38). The training set of breast samples used in the PAM50 assay is 50% clinically ER+,
therefore the mRNA-seq data were normalized to reflect the training set (https://
genome.unc.edu/pubsup/breastGEO/Guide%20to%20Intrinsic%20Subtyping
%209-6-10.pdf). Based on clinical data taken from the TCGA Data portal on September,
2012 (https://tcga-data.nci.nih.gov/tcga/), of the 728 samples, 157 were ER−, 535 were ER+,
2 were ER-indeterminate, 29 did not have ER status assays performed, and 5 did not have
available data, indicating that 77% of the mRNA-seq samples were ER+. To normalize the
data similar to the PAM50 training dataset, in which 50% of samples are ER+, all 157 ER−
samples were selected, as well as 157 randomly selected ER+ samples. The median gene
expression for the PAM50 intrinsic gene list was calculated based on this subset of samples.
To perform platform correction for mRNA-seq, these median values were then subtracted
from all 728 samples prior to running the PAM50 assay as previously described(38) (https://
genome.unc.edu/pubsup/breastGEO/PAM50.zip). Due to the short median follow-up time
(17 months) of the TCGA data set, survival analysis of gene expression signatures were
carried out using a microarray-based gene expression data set of 855 breast tumors with
published intrinsic subtype calls (140 basal-like, 90 claudin-low, 144 HER2-enriched, 243
Luminal A, 162 Luminal B, 76 Normal-like) and clinical data (combined data from the
following data sets: GSE2034, GSE12276, GSE2603, and the NKI295 (microarray-
pubs.stanford.edu/wound_NKI/Clinical_Data_Supplement.xls)) (39). Survival analyses of
BCR segment expression, however, used the TCGA RNA-seq data set. For all analyses of
ovarian cancer, we used the TCGA serous ovarian cancer mRNA-seq data set, which, like
the breast cancer data set, represents new mRNA-seq data, again using Illumina 2 × 50bp
sequencing, on a subset of the 500 cases from the TCGA Ovarian project (29). This mRNA-
seq data set consists of 266 tumors with follow-up data (https://tcga-data.nci.nih.gov/tcga/,
https://cghub.ucsc.edu/). The TCGA barcodes and genomic subtypes of all breast and
ovarian mRNA-seq samples are included as Supplementary Data 1. Unique sample IDs for
downloading TCGA mRNA-seq data from CGHub are included as Supplementary Data 3.
Gene Expression Signatures and Survival Analyses
Immune gene expression signatures were established using unsupervised hierarchical
clustering of mRNA-seq expression data for 728 breast tumor samples (see supplementary
data). Gene dendrogram nodes corresponding to genes characteristically expressed in
specific immune cell types were identified and validated through DAVID functional
annotation clustering and IPA (Ingenuity®Systems, www.ingenuity.com)(40, 41). Gene lists
for all five signatures are included in Supplementary Data 2. Additional lymphocyte gene
signatures were obtained from published studies: IGG_Cluster(11), B_Cell(42), and
B_Cell_60gene(12) are B-cell signatures, and T_Cell(42), CD8(42), LCK(43), and
TNBC_T-Cell(15) are T-cell signatures, with the CD8 signature specifically representing
CD8+ T-cells.
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Survival analyses were performed by Kaplan-Meier analysis and log-rank testing, and
hazard ratios were derived from the Cox proportional hazards model. For analysis of the
prognostic value of BCR segment expression, samples were divided into high and low
expression groups of equal number for Kaplan-Meier analysis and log-rank testing. To
evaluate the prognostic value of gene expression signatures, the Cox proportional hazards
model was used with each signature tested as a continuous variable. Multivariate survival
analysis was performed by ANOVA comparing individual Cox proportional hazards models.
To provide a control for the number of prognostic BCR gene segments, 353 (the number of
BCR gene segments tested) random genes were selected and p values were calculated for the
association of each of these genes with overall survival (breast) or progression-free survival
(ovarian) as in the BCR gene segments. The number of significant (p < 0.05) p values was
calculated from this set and 95% confidence intervals were calculated through bootstrap
resampling.
B-Cell Receptor Diversity
The method for estimating sequence diversity of a BCR gene segment for an individual
sample/tumor using paired-end mRNA-seq data is outlined in Supplementary Figure 3. Read
pairs mapping to the EntrezGene genomic location (www.ncbi.nlm.nih.gov/entrez/
query.fcgi?db=gene)(44) of a given BCR gene segment were identified (mapped by
MapSplice(45)). The sequence of these read pairs was compared to the hg19 reference
genome to identify non-reference bases. The genomic position and nucleotide identity of all
non-reference bases was identified for each read pair. Each observed pattern of non-
reference bases was then assigned a score representing the number of read-pairs containing
exactly that pattern of non-reference bases. This set of observed patterns and their
corresponding count was used to calculate the effective number of species, which is a
diversity function isomorphic to Shannon entropy, as described by Jost et al.(46).
De novo Assembly and Somatic Hypermutation Analysis
De novo assembly of BCR variable (V) gene segments from paired-end mRNA-seq reads
was performed using the Assembly-Based Re-Aligner (ABRA) algorithm (Mose et al.,
manuscript in preparation). To generate ABRA contigs, unmapped reads and reads mapping
to a BCR variable region of interest were first split into overlapping k-mers where k=31. K-
mers that were comprised exclusively of non-ambiguous bases with quality score > 20 were
assembled into a de Bruijn graph. K-mers with fewer than 100 observations were then
pruned from the graph. The graph was then traversed to produce all possible contigs. This
set of contigs was used for somatic hypermutation analyses.
To determine if the sequence of a BCR variable gene segment was consistent with somatic
hypermutation, the reference sequence for that gene segment was first established by Smith-
Waterman alignment to each IMGT® (IMGT®, the international ImMunoGeneTics
information system® http://www.imgt.org (founder and director: Marie-Paule Lefranc,
Montpellier, France))(47–53) reference allele sharing the same gene segment family and
selection of the closest match. The segment sequence was compared to the reference
sequence, and mutated and non-mutated bases were counted within SHM hotspots (WRCY,
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RGYW, WA, and TW sequences) and non-hotspot regions(54). Mutated and non-mutated
(i.e., reference and non-reference) bases were counted again within CDRs. Chi-square
testing was used to determine if the distribution of mutated bases was consistent with the
mutation pattern expected in SHM; chi-square testing was conducted separately for the
whole V segment sequence and for CDRs.
The method for producing an overall estimate of the degree of somatic hypermutation for a
BCR variable segment in mRNA-seq data is outlined in Supplementary Figure 4. ABRA
contigs were first constructed for that V gene segment and quantitated by BWA paired-end
alignment(55) of all unmapped reads and reads mapping to that segment to the set of ABRA
contigs. Multiple mappings were allowed, as long as both read pairs mapped to the same
contig. For each contig, the number of SHM hotspot mutations, SHM hotspot nonmutated
bases, non-hotspot mutations, and non-hotspot non-mutated bases were counted for the
whole segment and within CDRs. This information was weighted by the BWA alignment
score for that contig. These weighted values were summed across all contigs and chi-
squared testing was used to determine if the mutation pattern across the whole segment or
within CDRs indicated the presence of SHM. For this analysis, only segments with a
number of mapped reads greater than or equal to 0.04 × the length in bp of the segment
(approximating even coverage of depth 2) were considered for sequence analysis in a given
sample.
Results
B-cell gene expression signatures are prognostic in breast and ovarian cancer
Increased expression of B-cell gene signatures has been shown to be favorably prognostic in
breast cancer (11–13). To explore the role of B-cells and other lymphocyte cell types in the
different intrinsic subtypes of breast cancer, immune cell associated genomic signatures
were newly derived from unsupervised clustering of mRNA-seq data from 728 TCGA breast
cancer samples (Figure 1A). Gene dendrogram nodes containing characteristic lymphocyte
genes were selected as potential gene signatures. The identities of these signatures were
confirmed through functional annotation analysis and gene pathway-based analysis (40, 41).
These and other previously published lymphocyte gene signatures were used to confirm the
prognostic value of TILs on a genomic level, and to assess whether this benefit is isolated to
one or more intrinsic subtypes. We first evaluated a gene expression microarray data set of
855 breast tumors, using a univariate Cox proportional hazards model, for prognostic value
by subtype of lymphocyte gene signatures(39). For the newly derived B_Cell_cluster
signature derived from unsupervised clustering here, the IGG_cluster previously developed
by our group(11), and three B-cell gene signatures generated by others(12, 14, 15), overall
expression in breast tumors was greater in the basal-like and HER2-enriched subtypes
(Figure 2 A,C). Similar to previous work (12, 16, 56), high expression was associated with
better metastasis-free survival in basal-like and HER2-enriched tumors with greatest
difference in hazards in the basal-like subtype (Table 1).
We next performed a similar analysis on TCGA ovarian cancer data. Overall B-cell gene
signature expression was increased in immunoreactive ovarian tumors (Figure 2E–F).
Several B-cell gene signatures were prognostic for progression-free survival in the
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immunoreactive ovarian tumor subtype, which was not true for the other subtypes (Table 1).
T-cell signatures (14, 15, 43) were also evaluated, and showed a similar pattern of
expression and prognostic value (Fig 2B, D). In multivariate survival analysis of individual
immune signatures with other clinical and genomic features in breast cancer, most B-cell
and T-cell signatures remained significantly prognostic (Supplementary Table 1).
For both breast and ovarian tumors, B-cell gene signature expression strongly correlated
with other lymphocyte gene signatures, including those representing T-cells and
macrophages (Supplementary Figure 1). Likelihood ratio testing was performed to assess the
independence of immune gene signatures as predictors of survival. Conditioning on clinical
variables (node status, age, and hormone receptor status for breast; stage, grade, and age for
ovarian) and adding either B-cell or T-cell gene signatures to the model, only one gene
signature was needed to significantly improve the predictive power of the model (data not
shown). In accordance with the high degree of correlation between immune cell signatures,
adding further signatures for the same cell type did not improve the model. Each ordering of
immune signatures was tested to ensure this finding was not specific to specific signatures.
Including both B-cell and T-cell signatures in the model, in breast cancer only one signature
significantly improved the model; in ovarian, one B-cell signature and one T-cell signature
each significantly improved the model. Together, these analyses indicate an improved
outcome for patients with specific subtypes of breast and ovarian cancer. This correlated
with the presence of B-cells, plasmablasts and/or plasma cells in the tumor
microenvironment, which suggests a productive endogenous B/plasma cell response may be
present in the tumor microenvironment.
Specific B-cell receptor gene segment expression is prognostic in basal-like breast cancer
Next, we wished to determine if the B-cell gene signature found in patients with basal-like
breast cancer was consistent with an antigen-specific response. Other groups have shown
clonal expansion and somatic hypermutation in breast B-cell TILs, suggesting an
antigendirected response in those samples (18, 20, 22). Actively responding antigen-specific
B-cell populations are characterized by clonal expansion; thus, we expect B-cell clonal
expansion in patients where an effective, antigen-directed anti-tumor response is occurring.
Because the clonal diversity of a B-cell population can be inferred by the diversity of the
BCRs they express, there should be a prognostic benefit in samples with increased
expression of specific BCR gene segments (i.e. immunoglobulin heavy chain and light chain
variable, joining, diversity, and constant region segments). It has been shown that the BCR
protein from breast cancer TILs is mainly produced by plasma cells, not B-cells (13). Here,
we will continue to use the term “B-cell” to refer to the heterogeneous group of BCR-
producing cells in the B-cell lineage.
We first calculated the expression levels of all 353 BCR gene segments available in the
IMGT® database across the breast and ovarian tumor data. Breast HER2-enriched and
basal-like tumors, as well as ovarian immunoreactive and mesenchymal tumors, showed
high expression widely across BCR segments (Figure 3). We analyzed prognosis by
expression of each individual BCR segment, and then compared this to an identical number
of randomly selected genes using a bootstrap procedure to assess the significance of this
Iglesia et al. Page 7






















finding. In basal-like breast tumor subtypes, we identified a significantly greater number of
BCR segments predictive of overall survival than expected by random sampling (Figure
4A–B). No other breast cancer subtype demonstrated a greater number of prognostic BCR
segments than expected by chance (Figure 4A). Similarly, in patients with ovarian cancer
significantly more BCR segments were predictive of progression-free survival in
immunoreactive tumors than in the other subtypes (Figure 4C–D). The mesenchymal and
differentiated ovarian subtypes also showed significantly more prognostic BCR segments
than expected by chance. In breast tumors, this finding cannot be explained solely by
increased overall expression of BCR gene segments in the basal-like subtype, as the highest
expression of BCR segments was found in the HER2-enriched subtype (Figure 3).
Prognostic segments were discovered in multiple gene families including IgHV, IgHJ,
IgHC, IgKV, IgKJ, IgKC, IgLV, IgLJ, and IgLC. IgKC, which has been previously
identified as prognostic in several solid tumor types including breast cancer (13), predicted
progression-free survival in ovarian cancer but did not attain significance in the breast data
set. Individual representative plots of overall or progression-free survival by high vs. low
expression of representative prognostic segments are shown in Supplementary Figure 2.
Since B-cells undergo somatic hypermutation following antigen stimulation in the germinal
center reaction, reads mapping to each germline BCR gene segment are expected to contain
many corresponding single nucleotide variations. Each group of mapped reads
corresponding to a BCR gene segment would then exist as a population, the diversity of
which should inversely relate to the degree of clonal expansion in the tumor infiltrate. We
used the Shannon entropy index normalized as the effective number of species as a measure
of diversity(46). For this analysis, we calculated the diversity per patient of each BCR gene
segment; a description of this procedure is shown as Supplementary Figure 3. Basal-like,
HER2-enriched, and luminal B breast tumors, and immunoreactive ovarian tumors, include
a subset of tumors with high expression of low-diversity segments (Figure 5). This finding is
consistent with the presence of a clonally-expanded B-cell population within those tumor
subtypes that is absent in other subtypes.
Analysis of somatic hypermutation patterns in mRNA-seq data
Somatic hypermutation in BCR gene segments is characterized by mutations that favor
defined local sequence regional “hotspots” and CDRs, due to bias in the enzymatic activity
that facilitates the mutation process(36). In order to evaluate the degree of somatic
hypermutation represented in our data, we made use of the novel de novo assembly
algorithm ABRA to assemble unique contigs from reads that map to each BCR variable (V)
segment locus, followed by analysis of the contigs for the presence or absence of SHM.
These contigs allowed us to analyze SHM mutation patterns across a V segment or its
CDRs, rather than interrogating each mRNA-seq read pair separately. An overview of this
method is given as Supplementary Figure 4.
We applied our method of analyzing somatic hypermutation in mRNA-seq data to the
TCGA breast and ovarian data sets. For the top 10 most highly expressed BCR V gene
segments in breast or ovarian tumors in our data sets, the basal-like and HER2-enriched
breast subtypes were enriched for tumors with V gene segments consistent with SHM
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(Supplementary Figure 5). Immunoreactive ovarian tumors showed a high proportion of
segments with mutation patterns suggestive of SHM, but it was not significantly higher than
the proportion observed in other ovarian subtypes. The presence of SHM sequence
characteristics from TILs is suggestive of the presence of antigen-experienced B-cells,
potentially against tumor antigens, in the tumor microenvironment.
Discussion
We define here four characteristics of an active, antigen-driven, anti-tumor B-cell response
that can be identified from mRNA-seq data, namely: 1) increased expression and prognostic
value of B-cell gene signatures, 2) increased expression and prognostic value of BCR gene
segments, 3) decreased diversity of highly expressed BCR gene segments, and 4) mutation
patterns consistent with BCR somatic hypermutation. All four conditions were found in
basal-like breast cancers, and three of these conditions were found for immunoreactive
ovarian tumors and HER2-enriched breast tumors. These findings support the hypothesis
that a productive B-cell-driven endogenous anti-tumor response may be generated in many
basal-like breast and immunoreactive ovarian carcinomas. To our knowledge this represents
the first inference of BCR repertoire characteristics from mRNA-seq data.
Investigations into the anti-cancer adaptive immune response have largely been focused on
T-cells. Accordingly, current cancer immunotherapy is directed at modifying the T-cell
immune response through modulating targets like CTLA4 and PD-L1. In this work, we
show that the presence of tumor-infiltrating B-cells correlated with overall and progression-
free survival suggesting that B-cells play an important role in anti-tumor immunity. We do
show that the expression of B-cell genes was highly correlated with the expression of T-cell
genes. By further demonstrating that in specific breast and ovarian cancer subtypes B-cell
TILs are clonally expanded and enriched for somatic hypermutation, we provide evidence
that B-cell TILs are not merely a surrogate marker for an anti-tumor T-cell response. While
it is technically possible that previously expanded B-cell clones may be trafficked to the
tumor independent of their antigen binding capability, previous studies showing clonal
evolution within breast tumors make this unlikely(19–22), as does the association with
specific tumor subtypes. Tumor antigen-directed B-cell responses, which we suggest are
present in many basal-like breast and immunoreactive ovarian tumors, may provide a novel
way to clinically target these tumor types. Interestingly PD-1 (PDCD1), which is expressed
on activated T and B-cells, is currently a very promising target for immunotherapy. Previous
work has shown that blocking the interaction of PD-1 with PDL1 and PDL-2 (PDCD1LG2)
enhances the activation, proliferation, and cytokine production of human B-cells in the
presence of TLR stimulation(57). As immunotherapy advances in breast cancer, it will be
important to evaluate B-cell TILs to investigate if and how anti-cancer immunotherapies
may modulate the B-cell compartment.
As more immunomodulatory treatments become available for cancer therapy, one critical
issue is the identification of the specific cancer patients who may benefit from such therapy.
This work highlights the subtype association of clonally restricted B-cell responses.
Previous studies in ovarian cancer have been mixed as to the importance of B-cell TILs,
perhaps because of the heterogeneity of the B-cell response across the subtypes of ovarian
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cancer. Milne, et al. highlighted the high-grade serous histologic subtype as being
selectively associated with TILs predictive of disease-specific survival(32). Here, we further
identify the immunoreactive genomic subtype of serous ovarian cancer as containing
prognostic TILs. Among basal-like breast tumors, it is interesting to note that patients with
high B-cell infiltration as assessed by gene signatures were also significantly younger than
other patients with basal-like breast cancer (data not shown), corroborating previous work
highlighting this group(58).
Other investigations of B-cell TILs in breast cancer have found the survival benefit
associated with B-cell gene expression to be dependent on proliferation (12, 13, 56).
However, we do not see this association in our data. While the basal-like and HER2-
enriched subtypes are both highly proliferative, we observed no survival benefit for B-cell
TILs in luminal B tumors, which are also characterized by high proliferation. Furthermore,
likelihood ratio testing conditioning on clinical variables and genomic subtype (data not
shown) demonstrated that proliferation did not significantly increase the predictive ability of
the model in breast cancer.
This work again underscores the similarity between basal-like breast and ovarian tumors.
Previous genomic studies have established that serous ovarian tumors resemble basal-like
breast cancer in terms of their mutational profiles and DNA copy number changes(24). Here
we show that this similarity extends to the immune component of the tumor
microenvironment. In terms of the immune response, basal-like breast cancer bears more
similarity to ovarian immunoreactive cancer than to the luminal A breast cancer subtype.
This adds further weight to the notion that the therapeutic approach to basal-like breast and
ovarian cancer could be similar.
The claudin-low subtype of breast cancer is also known to have abundant TILs(26), which
we confirm by expression of TIL gene signatures (Figure 2A–B). However, unlike the basal-
like and HER2-enriched subtypes, TIL abundance was not associated with a survival benefit
within claudin-low tumors (Table 1). This could potentially be due to different
immunosuppressive mechanisms within the tumor microenvironment, or it is possible that
claudin-low tumors elicit a nonspecific inflammatory response in contrast with other high-
immune breast tumors. We were unable to assess the BCR sequence diversity of claudin-low
TILs as very few (fewer than ten) claudin-low tumors have been identified within the TCGA
data set. If TILs within claudin-low tumors are not productive or antigen-directed,
misclassification of these tumors may limit the effectiveness of immunomodulatory
treatments within triple-negative breast cancers.
There are several standard approaches to analyzing the adaptive immune response present in
the tumor microenvironment and tumor-draining lymph node. Immunohistochemistry and
immunofluorescence can be performed, although specific antibodies often require frozen
tissue; similarly, flow cytometry can be performed on frozen tissue. One of the benefits of
the approach described here is the potential to perform the analysis on formalin-fixed
paraffin embedded tissue as methods for mRNA-seq from these samples have been
demonstrated(59), and will continue to improve and become standardized. As this is
available on a substantially greater number of patients compared to frozen tissue, this
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approach could allow for a much larger group of patients to be analyzed for the presence of
adaptive immune signatures. Indeed, there are a large and growing number of human tissue
samples with available mRNA-seq data; through the methods described here, these samples
may be analyzed for antigen-directed B-cell responses.
Given our data that the presence of B-cells in the tumor microenvironment in patients with
basal-like and HER2-enriched breast cancers and immunoreactive ovarian cancer is
predictive of outcome, the role that endogenous B-cells play at these sites of tumor growth is
a critical question. Plasma cells could generate anti-tumor antibodies that could be important
in the early control of the growth of breast cancer cells, but which may ultimately become
lost during tumor progression. Alternatively, B-cells may function as antigen-presenting
cells to activate tumor-specific T-cells, which in turn may be inhibited via
immunosuppressive mechanisms such as the PD-1/PD-L1 interaction. Future work is needed
to determine the mechanism by which B-cells affect tumor growth in these different
molecular subtypes of cancer, and if and how this could be harnessed to improve
endogenous anti-tumor immune responses.
The most difficult breast tumors to treat clinically are often of the “triple-negative” class,
defined as such by the lack of cell-surface expression of estrogen receptor, progesterone
receptor, and HER2(60). The majority (60–80%) of triple-negative tumors are basal-like
(61), and thus the basal-like subtype represents a critical target for the development of novel
therapeutics. The presence of BCR characteristics associated with overall survival and
consistent with a productive anti-tumor endogenous B-cell response suggests that methods
to enhance or induce anti-tumor B-cells in patients with basal-like breast cancer may be
clinically efficacious.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Statement of Translational Relevance
Immunomodulatory therapies such as those targeting CTLA4 and PD-L1 (CD274) have
been shown to be effective in a number of tumor types. These treatments primarily target
the T-cell component of the adaptive immune system. In this work, we provide further
evidence that tumor-infiltrating B-cells are also important in anti-tumor immunity in
basal-like breast and immunoreactive ovarian cancer, suggesting that immunomodulatory
therapy may be effective in these tumor types. By identifying basal-like breast cancer as
an important setting for immunomodulatory treatment, we provide a rationale for the use
of targeted therapies in many clinically triple-negative breast cancers, where no targeted
therapies currently exist.
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A Concordant expression of genes from different immune cell types in a distinct subset of
primarily basal-like, HER2-enriched, and normal-like tumors. Unsupervised hierarchical
clustering of breast cancer mRNA-seq data (n=728); signatures B_Cell_cluster,
CD8_cluster, T_Cell_cluster, CD68_cluster, and MacTh1_cluster are derived from this
hierarchical clustering. B Expression of breast cancer-derived gene expression signatures in
an ovarian cancer mRNA-seq data set (n=266).
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Box plots of expression of IGG_Cluster and CD8 gene expression signatures by subtype,
with one-way ANOVA p value, in A, B microarray data from 855 breast tumors C, D
mRNA-seq data from 819 breast samples (728 tumor, 91 normal breast) and 266 ovarian
tumors E, F mRNA-seq data from 266 ovarian tumors. Expression of immune genes is high
in basal-like, claudin-low, and HER2-enriched breast cancer subtypes and the
immunoreactive ovarian cancer subtype.
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Expression level of all BCR segments across breast cancer subtypes and ovarian cancer.
Expression is highest in basal-like and HER2-enriched breast cancer and immunoreactive
ovarian cancer subtypes and highly correlated within groups.
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Expression level of BCR segments is preferentially predictive of improved overall survival
in basal-like breast cancer and progression-free survival in immunoreactive ovarian cancer.
A, C Grid of prognostic value of all BCR segments (colored cells represent positively
prognostic segments). B, D Prognostic BCR segment distribution across subtypes, with
bootstrap confidence intervals (95%). Control value represents 353 random non-BCR genes.
Iglesia et al. Page 19























A Basal-like, HER2-enriched, and luminal B tumors show high expression of low-diversity
BCR V segment pools (data averaged over top ten highest expressed V segments). B
Density of V segment expression in breast cancer. C A subset of predominantly
immunoreactive ovarian tumors show high expression of low-diversity BCR V segment
pools (data averaged over top ten highest expressed V segments). D Density of V segment
expression in ovarian cancer.
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